Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment

Figures & data

Table 1 Characteristics of patients prior to the study

Age (years)	73.9±9.1
Sex (F:M)	98:0
BMI (kg/m^2)	21.5±4.0
Serum BAP (µg/L)	16.2±7.2
Serum TRACP-5b (mU/dL)	496.7±251.4
BP pretreatment, n	36
PTH combination, n	43
Vitamin D combination, n	66
1. Native vitamin D and calcium, n	40
2. Alfacalcidol, n	10
3. Eldecalcitol, n	13
4. Calcitriol, n	3
L-BMD (g/cm^2)	0.799±0.15
H-BMD (g/cm^2)	0.635±0.11

Notes: Results are expressed as mean ± standard deviation. p<0.05 was considered statistically significant.

Abbreviations: BAP, bone alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; H-BMD, total hip BMD; L-BMD, lumbar 1–4 BMD; PTH, teriparatide; TRACP-5b, tartrate-resistant acid phosphatase 5b.

Figure 1 Comparisons of percent changes in L-BMD and H-BMD between TRACP-5b (<420 mU/dL) and TRACP-5b (≥420 mU/dL) groups just prior to and during denosumab administration (A, B). Comparisons of percent changes in L-BMD and H-BMD in BAP (<14.5 µg/L)and BAP (≥14.5 µg/L) groups just prior to and during denosumab administration (C, D). *p<0.05; **p<0.01; ^#p<0.05; ^##p<0.01. Results are expressed as mean ± standard error.

Abbreviations: BAP, bone alkaline phosphatase; BMD, bone mineral density; H-BMD, total hip BMD; L-BMD, lumbar 1–4 BMD; TRACP-5b, tartrate-resistant acid phosphatase 5b.

Table 3 Patient characteristics prior to the study after classification of BAP values, and L-BMD and H-BMD values at 0, 4, 8, and 12 months of denosumab treatment

Characteristic	BAP (<14.5 µg/L) (n=45)	BAP (≥14.5 µg/L) (n=53)	p-value
Age (years)	73.1±8.0	74.1±9.9	0.60
BMI (kg/m^2)	21.3±2.7	22.0±4.7	0.37
Serum BAP (µg/L)	10.3±2.8	22.2±7.4	<0.001
Serum TRACP-5b (mU/dL)	336.3±150.3	624.7±252.4	<0.001
BP pretreatment, n	28	11
Duration of BP use, years	3.6±3.2	4.7±7.1	0.72
PTH combination, n	15	29
L-BMD (g/cm^2) at 0 month	0.778±0.12	0.796±0.17	0.51
H-BMD (g/cm^2) at 0 month	0.661±0.10	0.630±0.11	0.17
L-BMD (g/cm^2) at 4 months	0.794±0.10	0.817±0.10	0.33
H-BMD (g/cm^2) at 4 months	0.678±0.10	0.640±0.12	0.13
L-BMD (g/cm^2) at 8 months	0.796±0.11	0.830±0.10	0.14
H-BMD (g/cm^2) at 8 months	0.681±0.10	0.640±0.09	0.09
L-BMD (g/cm^2) at 12 months	0.816±0.11	0.839±0.15	0.48
H-BMD (g/cm^2) at 12 months	0.688±0.09	0.641±0.12	0.11

Notes: Results are expressed as mean ± standard deviation. p<0.05 was considered statistically significant.

Abbreviations: BAP, bone alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; H-BMD, total hip BMD; L-BMD, lumbar 1–4 BMD; PTH, teriparatide; TRACP-5b, tartrate-resistant acid phosphatase 5b.

Table 2 Patient characteristics prior to the study after classification of TRACP-5b values, and L-BMD and H-BMD values at 0, 4, 8, and 12 months of denosumab treatment

Characteristic	TRACP-5b (<420 mU/dL) (n=47)	TRACP-5b (≥420 mU/dL) (n=51)	p-value
Age (years)	73.2±8.5	74.1±8.8	0.59
BMI (kg/m^2)	22.0±3.7	21.5±4.2	0.52
Serum BAP (µg/L)	11.8±4.6	21.3±8.4	<0.001
Serum TRACP-5b (mU/dL)	283.9±99.3	683.3±197.5	<0.001
BP pretreatment, n	32	7
Duration of BP use, years	2.9±2.5	9.9±8.3	0.20
PTH combination, n	19	25
L-BMD (g/cm^2) at 0 months	0.796±0.11	0.783±0.17	0.64
H-BMD (g/cm^2) at 0 months	0.664±0.10	0.640±0.10	0.24
L-BMD (g/cm^2) at 4 months	0.825±0.10	0.830±0.10	0.83
H-BMD (g/cm^2) at 4 months	0.666±0.07	0.656±0.10	0.63
L-BMD (g/cm^2) at 8 months	0.832±0.09	0.839±0.10	0.75
H-BMD (g/cm^2) at 8 months	0.674±0.10	0.665±0.10	0.71
L-BMD (g/cm^2) at 12 months	0.850±0.11	0.854±0.11	0.88
H-BMD (g/cm^2) at 12 months	0.680±0.10	0.668±0.10	0.59

Notes: Results are expressed as mean ± standard deviation. p<0.05 was considered statistically significant.

Abbreviations: BAP, bone alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; H-BMD, total hip BMD; L-BMD, lumbar 1–4 BMD; PTH, teriparatide; TRACP-5b, tartrate-resistant acid phosphatase 5b.